Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor γ agonist in an in vivo mouse model of spontaneous breast cancer

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4935-

  Mustafa, Aladdin ^a   Kruger, Warren D ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; N (9 FLUORENYLMETHYLOXYCARBONYL)LEUCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; DISEASE COURSE; EXPERIMENTAL NEOPLASM; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PPAR GAMMA; PYRAZOLES; SULFONAMIDES; TIME FACTORS;

EID: 51049119421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0958     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2007.
2. Vogel VG. Chemoprevention strategies 2006. Curr Treat Options Oncol 2007;8:74-88.
3. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
4. Kundu N, Smyth MJ, Samsel L, Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 2002;76:57-64.
5. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N, Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res 2006;26:4245-54.
6. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12:1486-91.
7. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6:27.
8. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade [review]. Oncol Rep 2005;13:559-83.
9. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor- γ and levels of prostaglandin E2 and 15-deoxy- Δ12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003;103:84-90.
10. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9.
11. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor γ in malignant diseases. Crit Rev Oncol Hematol 2006;58:1-14.
12. Rocchi S, Picard F, Vamecq J, et al. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001;8:737-47.
13. Clay CE, Namen AM, Atsumi G, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999;20: 1905-11.
14. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 1994; 91:11236-40.
15. Shibata MA, Jorcyk CL, Liu ML, Yoshidome K, Gold LG, Green JE. The C3(1)/SV40 Tantigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol 1998;26:177-82.
16. Green JE, Shibata MA, Yoshidome K, et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000;19:1020-7.
17. Patocs A, Zhang L. Xu Y. et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases N Engl J Med 2007;357:2543 51.
18. Oesterreich S, Fuqua SA. Tumor suppressor genes in breast cancer. Endocr Relat Cancer 1999;6: 405-19.
19. Green JE, Shibata MA. Shibata E. et al. 2- Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res 2001;61: 7449-55.
20. Yokoyama Y, Green JE, Sukhatme VP, Ramaknshnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000;60:4362-5.
21. Xin B, Yokoyama Y, Shigeto T. Futagami M, Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor γ ligand, on the growth of human ovarian cancers Cancer 2007; 110:791-800.
22. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARγ by lovastatm and rosi glitazone. Int J Cancer 2006;118:2390-8
23. Yee LD. Williams N, Wen P, et al. Pilot study of rosiglitazone therapy in women with breast cancer effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007;13:246-52